Literature DB >> 16427496

Controversies in atrial fibrillation.

Stanley Nattel1, Lionel H Opie.   

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia, and contributes greatly to cardiovascular morbidity and mortality. Many aspects of the management of atrial fibrillation remain controversial. We address nine specific controversies in atrial fibrillation management, briefly focusing on the relations between mechanisms and therapy, the roles of rhythm and rate control, the definition of optimum rate control, the need for early cardioversion to prevent remodelling, the comparison of electrical with pharmacological cardioversion, the selection of patients for long-term oral anticoagulation, the roles of novel long-term anticoagulation approaches and ablation therapy, and the potential usefulness of upstream therapy targeting substrate development. The background of every controversy is reviewed and our opinions expressed. Here, we hope to inform physicians about the most important controversies in this specialty and stimulate investigators to address unresolved issues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16427496     DOI: 10.1016/S0140-6736(06)68037-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  36 in total

1.  Bisphosphonates and risk of atrial fibrillation: a meta-analysis.

Authors:  Seo Young Kim; Min Jung Kim; Suzanne M Cadarette; Daniel H Solomon
Journal:  Arthritis Res Ther       Date:  2010-02-19       Impact factor: 5.156

Review 2.  [Alcohol and arrhythmias].

Authors:  D Pfeiffer; D Jurisch; M Neef; A Hagendorff
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

Review 3.  Methylmalonic acid--an endogenous toxin?

Authors:  S Kölker; J G Okun
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

Review 4.  [Anticoagulation with atrial fibrillation].

Authors:  S Zellerhoff; A Goette; P Kirchhof
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

5.  A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy.

Authors:  S R Shunmugam; Conn Sugihara; Nick Freemantle; Patrick Round; Steve Furniss; Neil Sulke
Journal:  J Interv Card Electrophysiol       Date:  2018-02-19       Impact factor: 1.900

6.  Mathematical simulations of ligand-gated and cell-type specific effects on the action potential of human atrium.

Authors:  Mary M Maleckar; Joseph L Greenstein; Natalia A Trayanova; Wayne R Giles
Journal:  Prog Biophys Mol Biol       Date:  2009-01-30       Impact factor: 3.667

7.  Serological predictors for the recurrence of atrial fibrillation after electrical cardioversion.

Authors:  Sook Kyoung Kim; Hui-Nam Pak; Jae Hyung Park; Kyoung Jeong Ko; Jihei Sara Lee; Jin Wi; Jong Il Choi; Young-Hoon Kim
Journal:  Korean Circ J       Date:  2010-04-22       Impact factor: 3.243

Review 8.  Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure.

Authors:  George Karayannis; George Kitsios; Haralambos Kotidis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2007-04-21       Impact factor: 4.214

9.  The Connection between Cardiac and Mental Disorder: Atrial Fibrillation in Patients with Psychiatric Disorder.

Authors:  Fa-Po Chung; Yenn-Jiang Lin
Journal:  Acta Cardiol Sin       Date:  2014-01       Impact factor: 2.672

10.  Can we improve outcomes in AF patients by early therapy?

Authors:  Paulus Kirchhof
Journal:  BMC Med       Date:  2009-11-26       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.